17 September 2020: Clinical Research
Comparison of Clinical Outcomes in Patients with ST Elevation Myocardial Infarction with Percutaneous Coronary Intervention and the Use of a Telemedicine App Before and After the COVID-19 Pandemic at a Center in Beijing, China, from August 2019 to March 2020
Jing Nan 1ABCDEG* , Shuai Meng 1BCE* , Hongyu Hu 1CDE , Ruofei Jia 1DEF , Wei Chen 1DEF , Qun Li 1DE , Tong Zhang 1DEF , Ke Song 1DEF , Yang Wang 2ACDE* , Zening Jin 1ABDEF*DOI: 10.12659/MSM.927061
Med Sci Monit 2020; 26:e927061
Table 4 Comparison of the incidence of adverse events between the app user group and non-app user group before and after the COVID-19 pandemic.
| Patients before the pandemic(n=183) | *p value | Patients after the pandemic(n=60) | **p value | ***p value | |||
|---|---|---|---|---|---|---|---|
| App user group (n=25) | Non-App user group (n=158) | App user group (n=8) | Non-App user group (n=52) | ||||
| In-hospital adverse event | |||||||
| All-cause of death | 0 (0%) | 4 (2.5%) | 1.000 | 1 (12.5%) | 8 (15.4%) | 1.000 | 0.001 |
| Cardiac death | 0 (0%) | 4 (2.5%) | 1.000 | 1 (12.5%) | 8 (15.4%) | 1.000 | 0.001 |
| MACE | 0 (0%) | 5 (3.2%) | 1.000 | 1 (12.5%) | 10 (19.2%) | 1.000 | 0.000 |
| Non-fatal myocardial infarction | 0 (0%) | 1 (0.6%) | 1.000 | 0 (0%) | 4 (7.7%) | 1.000 | 0.014 |
| Stroke | 0 (0%) | 0 (0%) | 1.000 | 0 (0%) | 1 (1.9%) | 1.000 | 0.247 |
| Any revascularization | 0 (0%) | 1 (0.6%) | 1.000 | 0 (0%) | 0 (0%) | 1.000 | 1.000 |
| Definite or probable stent thrombosis | 0 (0%) | 1 (0.6%) | 1.000 | 0 (0%) | 0 (0%) | 1.000 | 1.000 |
| New renal replacement therapy | 0 (0%) | 9 (5.7%) | 0.613 | 0 (0%) | 11 (21.2%) | 0.330 | 0.002 |
| 30-day adverse event | |||||||
| All-cause of death | 0 (0%) | 5 (3.2%) | 1.000 | 1 (12.5%) | 8 (15.4%) | 1.000 | 0.001 |
| Cardiac death | 0 (0%) | 5 (3.2%) | 1.000 | 1 (12.5%) | 8 (15.4%) | 1.000 | 0.001 |
| MACE | 0 (0%) | 10 (6.3%) | 0.362 | 2 (25%) | 15 (28.8%) | 1.000 | 0.000 |
| Non-fatal myocardial infarction | 0 (0%) | 3 (1.9%) | 1.000 | 0 (0%) | 8 (15.4%) | 0.582 | 0.001 |
| Stroke | 0 (0%) | 2 (1.3%) | 1.000 | 0 (0%) | 3 (5.8%) | 1.000 | 0.098 |
| Any revascularization | 0 (0%) | 1 (0.6%) | 1.000 | 0 (0%) | 2 (3.8%) | 1.000 | 0.152 |
| Definite or probable stent thrombosis | 0 (0%) | 1 (0.6%) | 1.000 | 0 (0%) | 1 (1.9%) | 1.000 | 0.434 |
| New renal replacement therapy | 0 (0%) | 9 (5.7%) | 0.613 | 2 (25%) | 13 (25%) | 1.000 | 0.000 |
| Frequencies are reported as n/total (%), unless otherwise specified. MACE – major cardiovascular event. * Comparison between App user and non-App user group after the pandemic; ** comparison between App user and non-App user group after the pandemic; *** comparison between patients before and after the pandemic. | |||||||